



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **ANNOUNCEMENT ON FIRST QUARTERLY RESULTS FOR 2022**

### **CHARACTERISTICS OF GEM (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)**

**GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.**

**Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.**

*Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement, for which the directors of Tianjin TEDA Biomedical Engineering Company Limited (“the Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no matters the omission of which would make any statement herein or this announcement misleading.*

## HIGHLIGHTS

- Consolidated turnover of the Group for the three months ended 31 March 2022 amounted to RMB89,195,530, representing a decrease of 28.30% as compared to the same period of last year (31 March 2021: RMB124,407,625).
- Consolidated gross profit of the Group for the three months ended 31 March 2022 amounted to RMB5,489,781, representing a decrease of 59.99% as compared to the same period of last year (31 March 2021: RMB13,722,640).
- Loss attributable to equity owners of the Company for the three months ended 31 March 2022 was RMB6,043,544 (31 March 2021: loss of RMB165,625); loss per share of the Company was RMB0.319 cents; while loss per share for the same period of last year was RMB0.009 cents.
- The Board does not recommend the payment of dividends for the three months ended 31 March 2022.

## QUARTERLY RESULTS (UNAUDITED)

The board of directors (the “Board”) of Tianjin TEDA Biomedical Engineering Company Limited (the “Company”) is pleased to announce the unaudited quarterly results of the Company and its subsidiaries (hereafter collectively referred to as the “Group”) for the three months ended 31 March 2022, together with the comparative figures of the corresponding period in 2021 as follows

		<b>(Unaudited)</b>	
		<b>For the three months</b>	
		<b>ended 31 March</b>	
		<b>2022</b>	2021
	<i>Notes</i>	<b>RMB</b>	<b>RMB</b>
Revenue	2	<b>89,195,530</b>	124,407,625
Cost of sales		<b><u>(83,705,749)</u></b>	<u>(110,684,985)</u>
Gross profit		<b>5,489,781</b>	13,722,640
Other income and net loss		<b>26,569</b>	140,814
Selling and distribution costs		<b>(4,263,313)</b>	(7,828,413)
R&D and administrative expenses		<b>(6,621,896)</b>	(7,455,064)
Finance costs		<b><u>(742,591)</u></b>	<u>(73,225)</u>
Loss before taxation		<b>(6,111,450)</b>	(1,493,248)
Income tax	3	<u>—</u>	<u>—</u>
<b>Loss for the period</b>		<b><u>(6,111,450)</u></b>	<u>(1,493,248)</u>
<b>Attributable to:</b>			
Owners of the Company		<b><u>(6,043,544)</u></b>	<u>(165,625)</u>
Non-controlling interests		<b><u>(67,906)</u></b>	<u>(1,327,623)</u>
Loss per share – Basic ( <i>RMB</i> )	4	<b><u><u>(0.319) cents</u></u></b>	<b><u><u>(0.009) cents</u></u></b>

Notes:

## 1. BASIS OF PRESENTATION AND ACCOUNTING POLICIES

The financial statements have been prepared under the historical cost convention and in accordance with Hong Kong Financial Reporting Standards, accounting principles generally accepted in Hong Kong, the disclosure requirements of the Hong Kong Companies Ordinance and the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “GEM Listing Rules”). In the current period, the Group has adopted all of the new and revised Hong Kong Financial Reporting Standards (“HKFRSs”) and Hong Kong Accounting Standards (“HKASs”) (collectively “HKFRSs”) issued by the Hong Kong Institute of Certified Public Accountants which are relevant to its operations and effective for accounting periods beginning on or after 1 January 2011. The application of the new HKFRSs has had no material impact on the Group’s unaudited results of operations and financial position. The financial statements have been prepared on a going concern basis, assuming that the Group will continue to operate as a going concern. The validity of the Group’s ability to continue as a going concern depends on the success of the Group’s future operations. Consequently, the Directors have prepared the unaudited quarterly results for the three months ended 31 March 2022 on the going concern basis. The principal accounting policies adopted are consistent with those used in the preparation of the Group’s annual financial statements for the year ended 31 December 2021.

## 2. REVENUE

Revenue, which is also the Group’s revenue, represents the invoiced value of goods sold to customers after any allowance and discounts and is analysed as follows:

	For the three months ended 31 March	
	2022	2021
	RMB	RMB
Fertilizer products	89,086,907	124,379,590
Elderly care and health care services	<u>108,623</u>	<u>28,035</u>

## 3. INCOME TAX

### (a) Enterprise income tax (“EIT”)

Pursuant to the income tax rules and regulations of the PRC, the income tax of the Company and subsidiaries of the Group is calculated based on the statutory tax rate of 25% (2021: 25%), except for the following subsidiaries.

Guangdong Fulilong Compound Fertilizers Co., Ltd. is recognized as a High and New-Tech enterprise according to the PRC tax regulations and is entitled to a preferential tax rate of 15% (2021: 15%).

Pursuant to the rules and regulations of the Cayman Islands, the Group’s subsidiaries incorporated in the Cayman Islands are not subject to any income tax. The Group’s subsidiaries incorporated in Hong Kong are not liable for profits tax as they did not have any assessable income arising in Hong Kong during the period (2021: nil).

(b) **Income tax expense**

	<b>For the three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
Current Tax		
Hong Kong	Nil	Nil
Other Jurisdictions	—	—
	<u>                    </u>	<u>                    </u>

The income tax charge in Hong Kong is Nil for the three months ended 31 March 2022 (first quarter 2021: Nil) as the Company did not carry on any business in Hong Kong during the period. The income tax charge in the PRC is Nil for the three months ended 31 March 2022 (first quarter 2021: Nil).

The charge for the period can be reconciled to the profit per the income statement as follows:

	<b>For the three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
Loss before income tax expense	(6,111)	(1,493)
Tax calculated at the EIT rate of 25%	(1,528)	(373)
Tax rate differential	253	67
Effect of tax holiday exemption	—	—
Effect of the tax losses on consolidation	1,275	306
Tax effect of expenses that are not deductible in determining taxable profit	—	—
Tax expense for the period	—	—
	<u>                    </u>	<u>                    </u>

**4. LOSS PER SHARE**

The calculation of the basic loss per share attributable to owners of the Company is based on the following data:

	<b>For the three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB</b>	<b>RMB</b>
Loss for the purpose of basic earnings per share	(6,043,544)	(165,625)
<b>Number of shares</b>		
Weighted average number of ordinary shares for the purposes of basic loss per share	<u>1,894,500,000</u>	<u>1,894,500,000</u>

## DIVIDEND

The Board does not recommend the payment of an interim dividend for the three months ended 31 March 2022 (first quarter 2021: Nil).

## MOVEMENT OF RESERVES

	Share Capital		Share premium		Accumulated Losses		Capital reserve		Surplus reserve		Other reserve		Total	
	2022 RMB	2021 RMB	2022 RMB	2021 RMB	2022 RMB	2021 RMB	2022 RMB	2021 RMB	2022 RMB	2021 RMB	2022 RMB	2021 RMB	2022 RMB	2021 RMB
Balance as at 1 January	189,450,000	189,450,000	275,317,438	275,317,438	(350,863,515)	(308,608,472)	2,541,404	2,541,404	3,717,696	3,717,696	(19,382,403)	(19,382,403)	100,780,620	143,035,663
Loss attributable to equity holders of the Company for the three months ended 31 March	-	-	-	-	(6,043,544)	(165,625)	-	-	-	-	-	-	(6,043,544)	(165,625)
Issue of new shares	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March	<u>189,450,000</u>	<u>189,450,000</u>	<u>275,317,438</u>	<u>275,317,438</u>	<u>(356,907,059)</u>	<u>(308,774,097)</u>	<u>2,541,404</u>	<u>2,541,404</u>	<u>3,717,696</u>	<u>3,717,696</u>	<u>(19,382,403)</u>	<u>(19,382,403)</u>	<u>94,737,076</u>	<u>142,870,038</u>

# MANAGEMENT DISCUSSION AND ANALYSIS

## Business Review

Currently, the Group is principally engaged in two industry sectors: on one hand, it is the biological compound fertiliser business, which principally includes multiple series of biological compound fertiliser products that are used for the facilitation of balanced growth of grains, fruit and vegetables. On the other hand, it is the elderly care and health care business, which principally includes the comprehensive layout of elderly care services integrating medical services and elderly care services, and operation and management business that have strong demand with focus on the public with complete or partial disability or dementia. Such business mainly includes nationwide operation management development of elderly care institutions (service facilities), integration of elderly care service resources, supervision and consultancy on elderly care service management and other related elderly care service businesses. For the EEG detection business, expanding the EEG detection market in the PRC still needed a certain period of time, which had led to slower development in the EEG detection business.

## Financial Review

For the three months ended 31 March 2022, the Group achieved a consolidated turnover of RMB89,195,530, representing a decrease of 28.30% as compared to the same period of last year (31 March 2021: RMB124,407,625), the consolidated gross profit of the Group was RMB5,489,781, representing a decrease of 59.99% as compared to the same period of last year (31 March 2021: RMB13,722,640), and the consolidated gross profit margin of the Group was 6.15%, representing a decrease of 4.88% as compared to the same period of last year (31 March 2021: the consolidated gross profit margin was 11.03%).

For the three months ended 31 March 2022, loss attributable to the owners of the Company was RMB6,043,544 (31 March 2021: loss of RMB165,625); and loss per share of the Company was RMB0.319 cents as compared to loss per share of RMB0.009 cents of the same period in the previous year.

## **PLEDGE OF ASSETS AND CONTINGENT LIABILITIES**

As at 31 March 2022, the Group and the Company had contingent liabilities amounting to RMBNil (31 December 2021: RMB3,000,000) which was related to the guarantee provided by the Group and the Company in securing the bank loans granted to its subsidiaries.

## **EXPOSURE TO FOREIGN CURRENCY RISK**

The Group has relatively low foreign currency risk since all the sales of the Group are domestic sales in China primarily denominated in Renminbi and all payables to suppliers are also denominated in Renminbi.

## **TREASURY POLICIES**

The Group's bank borrowings are denominated in Renminbi and are usually renewed for one year upon maturity. Any surplus cash will be placed as deposits with the licensed banks in China.

## **FUTURE OUTLOOK**

With the gradual control of the global COVID-19 pandemic, the demand brought by the economic recoveries of China, the United States and Europe has improved. The rapid rise in bulk commodity prices may have ended, and has entered the stage of high level consolidation and diversification. Hence, the rapid rise in the price of compound fertilizer raw materials will also gradually come to an end. In addition, faced with a significant increase in raw materials prices, a large number of small-scale compound fertilizer enterprises gradually withdrew from the market, and the upstream and downstream markets of compound fertilizer will gradually recover. Under the backdrop of the global COVID-19 pandemic, the food safety issue has led to a certain increase in food prices, in which the corn prices have soared under the influence of supply and demand factors. The increase in food prices has driven farmers' willingness to farm, from which there has been considerable recovery and improvement in agricultural material consumptions and the farming industrial chain has been more prosperous. Under the big picture of currency over-issue, food prices are likely to remain high, which will considerably support the demands for compound fertilizers. The Company will strengthen marketing management, adjust product structure according to market demand, promote the production of compound fertilizers with high efficiency and intelligence, and strive to increase the market share.

On 11 May 2021, the National Bureau of Statistics released the seventh census data, with the population of 60 and above in China reached 264,000,000, accounting for 18.7%. Among which, the population of 65 and above reached 191,000,000, accounting for 13.5%. China’s aging population is becoming increasingly prominent and has become an inevitable social issue. In the meantime, China is facing the reality of a declining birth rate. Low birth rate and aging population have formed a distinct “population scissors”, showing the impending issue of aging population in China. On 17 June 2021, the National Development and Reform Commission, the Ministry of Civil Affairs and the National Health Commission jointly issued the “14th Five-Year Plan for Actively Responding to Population Aging Projects and Nursery Education Construction Implementation Plan” which promotes the implementation of the national strategy to actively respond to the aging population. With the continuous deepening of the aging population in China and the government’s emphasis on elderly care services, the elderly care service industry has become one of the “sunrise industries” with the greatest potential. For the elderly care business, in the current stage, the Group mainly operates under the asset-light operation model to provide management and consultation services to other elderly care institutions and elderly care realties and at the same time cooperate with world-leading elderly care institutions and to constantly enhance its own professional ability of elderly nursing. In addition, the Group will continue to vigorously expand the assistive equipment rental business. By leveraging on the numerous elderly care institutions entrusted to the Group in Shanghai, the Group aims to forge itself as one of the largest and most professional providers of assistive equipment rental service in Shanghai and across Yangtze River Delta.

## **SUPERVISORS’ INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES**

As at 31 March 2022, the interests of the directors and supervisors of the Company and their respective associates in the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”)) were as follows:

Long position in ordinary shares of RMB0.1 each in the Company:

Directors/Supervisors/Executive Officers	Personal	Family	Corporate	Other	Total	Percentage of
						issued share capital
Ms. Sun Li	–	–	300,000,000	–	300,000,000	15.83%
			(Note)			

*Note:* Out of these shares, 180,000,000 shares are held by Shenzhen Xiangyong Investment Company Limited (“Xiangyong Investment”) and 120,000,000 shares are held by Dongguan Lvye Fertilisers Company Limited (“Lvye Fertilisers”). Ms. Sun Li is the beneficial owner of Beijing Yingguxinye Investment Co., Ltd. (“Yingguxinye”) holding its 15% equity interest, while Yingguxinye holds 100% equity interest in Xiangyong Investment and Lvye Fertilisers, respectively. All of the shares represent domestic shares.

Save as disclosed in this paragraph, as of 31 March 2022, none of the Directors, the Supervisors or other chief executives of the Company had interest in any securities and underlying shares and debentures of the Company or any of its associated corporations, which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO); or (b) pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (c) otherwise notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by directors to be notified to the Company and the Stock Exchange.

## **DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES**

At no time during the period under review was the Company, its subsidiaries or its holding companies a party to any arrangement which enables the directors and the supervisors of the Company or their respective spouses or children under 18 years of age, to gain profit through acquiring the shares of the Company.

## **SUBSTANTIAL SHAREHOLDERS**

As at 31 March 2022, the following persons (other than the Directors and the Supervisors of the Company) had interests and short positions in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were notified to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept under Section 336 of the SFO:

Long position in ordinary shares of RMB0.1 each in the Company:

<b>Names of shareholders</b>	<b>Capacity</b>	<b>Number of ordinary shares</b>	<b>Percentage of issued share capital</b>
Tianjin Economic and Technological Development Area State Asset Operation Company ("State Asset Operation")	Beneficial owner	182,500,000 (Note)	9.63%
Shenzhen Xiangyong Investment Company Limited ("Xiangyong Investment")	Beneficial owner	180,000,000 (Note)	9.50%
Guangdong Jiamei Ecological Technology Co., Ltd. ("Guangdong Jiamei")	Beneficial owner	180,000,000 (Note)	9.50%
Dongguan Lvye Fertilisers Company Limited ("Lvye Fertilisers")	Beneficial owner	120,000,000 (Note)	6.33%

*Note:* All of the shares represent domestic shares.

Save as disclosed above, as at 31 March 2022, the Directors of the Company were not aware of any other person (other than the Directors and the Supervisors of the Company) who had an interest and short position in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were notified to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept under Section 336 of the SFO and/or were directly or indirectly interested in 5% or more of the issued share capital carrying rights to vote in all circumstances at general meetings of the Company.

## **BACKGROUND AND CURRENT STATUS OF THE PROFIT GUARANTEE FROM SJKGC**

On 16 April 2016, the Company, Shu Ju Ku Inc. (referred to as the “SJK”) and SJK Greater China Ltd. (referred to as “SJKGC”) entered into an agreement (referred to as the “Agreement”), pursuant to which the Company agreed to purchase, and SJK agreed to sell 51% of the entire issued shares of SJKGC (referred to as the “Sale Shares”) to the Company. All conditions precedent under the Agreement had been fulfilled and the completion of acquisition took place on 17 March 2017. The Company had nominated Hong Kong Teda Biomedical Investment Limited, an indirect wholly owned subsidiary of the Company, as its nominee to hold the Sale Shares on its behalf.

According to the Agreement, SJK warrants to the Company that SJKGC in each of the three financial years of 2017, 2018 and 2019 will have an audited after tax profit of not less than US\$5,390,000. If the above guarantee is not met, SJK irrevocably agrees and guarantees that whilst SJKGC’s audited after tax profit is less than US\$5,390,000, SJK shall pay, in an appropriate manner, to SJKGC in the amount equal to US\$5,390,000 minus SJKGC’s actual audited after tax profit of that year. In respect of the completion of the 2017 profit guarantee, the audited net profit after tax of SJKGC for the year ended 31 December 2017 was approximately US\$2,922,000, the profit guarantee for the year ended 31 December 2017 had not been fulfilled. In order to comply with the terms of the Agreement, the Company and SJK entered into a memorandum on 16 January 2018, pursuant to which SJK confirmed that the Company will have the right of priority and entitlement of cash dividend in the amount of US\$2,750,000 for the year ended 31 December 2017 and that the said dividend will be settled to the Company by 30 November 2018. For details, please refer to the supplemental announcement of the Company published on the GEM website dated 26 April 2018. SJK has agreed that the dividend distribution would be made by SJKGC based on the audited net profit in 2017 through signing the shareholder’s resolution on 26 April 2018, at the same time, the Company confirmed SJK has fulfilled the profit guarantee commitment in 2017.

In respect of the fulfillment of the 2018 and 2019 profit guarantees, the audited net profit after tax of SJKGC for the year ended 31 December 2018 was US\$305,000, and the audited net profit after tax for the year ended 31 December 2019 was US\$411,000, the above profit guarantees for the years ended 31 December 2018 and 31 December 2019 had not been fulfilled. As of now, SJK had not effected the payment of guaranteed cash dividend to the Company. The Company has initiated the arbitration proceeding at the Hong Kong International Arbitration Centre on 3 September 2019, reached a settlement agreement with SJK on 31 December 2020, revised the settlement agreement, adjusted the Shareholders' Agreements and the Share Acquisition Agreement on 26 March 2021, and convened a special general meeting on 9 September 2021, on which the revised settlement agreement and the revised or supplemented Shareholders' Agreements and Share Acquisition Agreement were considered and approved. For details, please refer to the announcements of the Company dated 4 September 2019, 17 July 2020, 7 January 2021, 26 March 2021, 26 July 2021 and 9 September 2021 published on the GEM website.

## **COMPETING INTERESTS**

During the three months ended 31 March 2022, none of the directors, the supervisors, or the management shareholders and their respective associates of the Company (as defined under the GEM Listing Rules) competes or may compete with the business of the Group or has or may have any other conflicts of interest with the Group required to be disclosed pursuant to the GEM Listing Rules.

## **AUDIT COMMITTEE**

The Company has established the audit committee and formulated the written terms of reference in compliance with the GEM Listing Rules and by reference to the "Guidelines for The Establishment of An Audit Committee" published by the Hong Kong Institute of Certified Public Accountants. The audit committee provides an important link between the Board and the Company's auditor in matters coming within the scope of the Group's audit. The primary duties of the committee are to review and supervise the financial reporting process of the Group. It also reviews the effectiveness of the external audit, internal controls and risk evaluation. As at the date of this announcement, the audit committee of the Company comprises three independent non-executive directors, namely Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun, among whom, Mr. Li Xudong has been appointed as the chairman of the committee due to his professional qualifications in accounting and auditing experience.

The audit committee has reviewed the first quarter results and the first quarter report of the Group for the three months ended 31 March 2022.

## **SHARE OPTION SCHEME**

The Company had not approved any new share option scheme during the period ended 31 March 2022.

## **MANAGEMENT CONTRACTS**

No contracts concerning the management or administration of the whole or any substantial part of the business of the Company were entered or existed during the period ended 31 March 2022.

## **PURCHASE, SALE OR REDEMPTION OF SECURITIES**

The Company did not redeem any of its shares during the period under review. Neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's shares during the period ended 31 March 2022.

## **CORPORATE GOVERNANCE PRACTICES**

The Board and the management of the Company have always endeavored to apply the code provisions as set out in the Corporate Governance Code (the "Code") contained in Appendix 15 of the GEM Listing Rules to the internal operations of the Group. The corporate governance principles on which the Company is complying emphasise an efficient board of directors and sound internal control, as well as the transparency presented to all of the shareholders. The directors are of the view that, the Company had complied with all the provisions of the Code during the period under review.

By order of the Board

**Tianjin TEDA Biomedical Engineering Company Limited**

**Sun Li**

*Chairman*

Tianjin, the PRC, 10 May 2022

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.*

*This announcement will remain at the "Latest Listed Company Information" page on the GEM website at <http://www.hkgem.com> for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*